European Society of Cardiology announces winners of innovative cardiovascular research grant programme

201

The winners of the European Society of Cardiology competitive research programme ‘Grants for Medical Research Innovation’ have been announced. The grants are awarded to research projects that will address areas of unmet medical need in thromboembolic disease.

“We were astounded at the quantity and quality of the proposals submitted. The judges had an extremely difficult task, even selecting five winners instead of four as originally planned”, says Francesco Cosentino, from Karolinska, Stockholm, the chairperson of the programme’s Scientific Committee. “With one in four people dying as a result of thromboembolic disease, innovative research in this field is urgently needed. We look forward to supporting the winners to advance knowledge in this important area.”

The five winners were selected from 554 entry submissions by leading researchers and institutes worldwide and will provide important insights into cardiovascular care.

The grant winners and awardees are:

  • David-Alexandre Trégouët, Pierre & Marie Curie Medical School, Paris, France
  • Timo Heidt, Heart Center Freiburg University, Freiburg, Germany
  • José Manuel Soria Fernandez, Institute of Biomedical Research – Hospital de la Sant Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain
  • Christina Christersson, Uppsala University, Uppsala, Sweden
  • Michael Joner, CVPath Institute, Gaithersburg, Maryland, USA, and Deutsches Herzzentrum München, Munich, Germany

 

According to the European Society of Cardiology (ESC) president, Fausto Pinto, says, “The ESC has a major commitment to support cardiovascular research. These grants, supported by Boehringer Ingelheim, are an excellent example of transparent partnership between industry and the scientific world. Supporting this research is helping peoples’ lives.”

“We are grateful to be able to support the ESC and the grant recipients and look forward to seeing the outcomes in the near future. We trust that the results of the grant programme will drive innovation in cardiovascular science.” says Jörg Kreuzer, vice president of Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim.